Related Experiment Video
Updated: Oct 4, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Resveratrol ameliorates nutritional steatohepatitis through the mmu‑miR‑599/PXR pathway
Lingbo Kong1, Xinyu An1, Lingxi Hu1
1Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Abstract:
The aim of the present study was to elucidate the effect of resveratrol on non‑alcoholic steatohepatitis (NASH), and the molecular basis in mice and Hepa1‑6 cells, in order to verify its therapeutic effect. C57BL/6J mice were fed a methionine‑choline‑deficient (MCD) diet to induce steatohepatitis and were treated with resveratrol. Mouse sera were collected for biochemical analysis and enzyme‑linked immunosorbent assay, and livers were obtained for histological observation, and mmu‑microRNA (miR)‑599 and inflammation‑related gene expression analysis. Hepa1‑6 cells were treated with palmitic acid to establish a NASH cell model, and were then treated with resveratrol, or transfected with mmu‑miR‑599 mimic, mmu‑miR‑599 inhibitor or recombinant pregnane X receptor (PXR) plasmid. Subsequently, the cells were collected for mmu‑miR‑599 and inflammation‑related gene expression analysis. Reverse transcription‑quantitative polymerase chain reaction and western blotting were used to assess mmu‑miR‑599 expression levels, and the mRNA and protein expression levels of PXR and inflammation‑related genes. The binding site of mmu‑miR‑599 in the PXR mRNA was verified by the luciferase activity assay. Mice fed an MCD diet for 4 weeks exhibited steatosis, focal necrosis and inflammatory infiltration in the liver. Resveratrol significantly reduced serum aminotransferase and malondialdehyde levels, and ameliorated hepatic injury. These effects were associated with reduced mmu‑miR‑599 expression, enhanced PXR expression, and downregulated levels of nuclear factor‑κB, tumour necrosis factor‑α, interleukin (IL)‑1β, IL‑6, NOD‑like receptor family pyrin domain‑containing protein 3 and signal transducer and activator of transcription 3. Administration of the mmu‑miR‑599 mimic inhibited PXR expression in Hepa1‑6 cells, whereas the mmu‑miR‑599 inhibitor exerted the opposite effect. A binding site for mmu‑miR‑599 was identified in the PXR mRNA sequence. Furthermore, overexpression of PXR inhibited the expression of inflammatory factors in Hepa1‑6 cells. The present study provided evidence for the protective role of resveratrol in ameliorating steatohepatitis through regulating the mmu‑miR‑599/PXR pathway and the consequent suppression of related inflammatory factors. Resveratrol may serve as a potential candidate for steatohepatitis management.
Insights
Resveratrol effectively treats non-alcoholic steatohepatitis (NASH) by regulating the mmu-miR-599/PXR pathway, reducing liver inflammation and injury. This study highlights resveratrol
Area of Science:
- Hepatology and Gastroenterology
- Molecular Biology
- Pharmacology
Background:
- Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by fat accumulation, inflammation, and hepatocellular injury.
- Current therapeutic options for NASH are limited, necessitating the exploration of novel treatment strategies.
Purpose of the Study:
- To investigate the therapeutic effects of resveratrol on non-alcoholic steatohepatitis (NASH) in a mouse model and Hepa1-6 cells.
- To elucidate the molecular mechanisms underlying resveratrol's action, focusing on the mmu-miR-599/PXR pathway and inflammatory responses.
Main Methods:
- Induction of steatohepatitis in C57BL/6J mice using a methionine-choline-deficient (MCD) diet, followed by resveratrol treatment.
- Establishment of a NASH cell model in Hepa1-6 cells using palmitic acid, with subsequent treatment with resveratrol, mmu-miR-599 mimic/inhibitor, or PXR plasmid.
- Analysis of liver histology, serum biochemistry, and gene/protein expression of mmu-miR-599, PXR, and inflammatory markers using RT-qPCR and western blotting.
- Luciferase activity assay to confirm the binding site of mmu-miR-599 in PXR mRNA.
Main Results:
- MCD diet-induced NASH in mice led to steatosis, necrosis, and inflammation, which were ameliorated by resveratrol treatment.
- Resveratrol significantly reduced liver injury markers and inflammatory gene expression (NF-κB, TNF-α, IL-1β, IL-6, NLRP3, STAT3).
- In Hepa1-6 cells, resveratrol decreased mmu-miR-599 expression and increased PXR expression, while mmu-miR-599 mimic inhibited PXR and its overexpression suppressed inflammatory factors. A direct interaction between mmu-miR-599 and PXR mRNA was confirmed.
Conclusions:
- Resveratrol demonstrates a protective role in ameliorating NASH by modulating the mmu-miR-599/PXR pathway.
- The mechanism involves the downregulation of mmu-miR-599, leading to increased PXR expression and subsequent suppression of inflammatory pathways.
- Resveratrol holds potential as a therapeutic candidate for managing NASH.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018